517870-18-7 Usage
Uses
Used in Pharmaceutical Research:
Methyl 5-(3-Nitrophenyl)isoxazole-3-carboxylate is used as a research compound for its potential biological activities, such as antimicrobial, antiviral, and anticancer properties. Its unique structure and properties make it a valuable tool in the development of new drugs and therapies.
Used in Organic Synthesis:
As a derivative of isoxazole, Methyl 5-(3-Nitrophenyl)isoxazole-3-carboxylate is used as a key intermediate in the synthesis of various organic compounds. Its reactivity and functional groups allow for the formation of new chemical bonds and the creation of diverse molecular structures.
Used in Agrochemical Products:
Methyl 5-(3-Nitrophenyl)isoxazole-3-carboxylate is used as a building block in the synthesis of agrochemical products, such as pesticides and herbicides. Its incorporation into these products can enhance their effectiveness and selectivity, leading to improved crop protection and yield.
Used in Drug Development:
Methyl 5-(3-Nitrophenyl)isoxazole-3-carboxylate is employed as a starting material or intermediate in the development of new pharmaceutical drugs. Its unique properties and potential biological activities make it a promising candidate for the treatment of various diseases and conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 517870-18-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,1,7,8,7 and 0 respectively; the second part has 2 digits, 1 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 517870-18:
(8*5)+(7*1)+(6*7)+(5*8)+(4*7)+(3*0)+(2*1)+(1*8)=167
167 % 10 = 7
So 517870-18-7 is a valid CAS Registry Number.
517870-18-7Relevant academic research and scientific papers
Synthesis and structure-activity relationship of new chalcone linked 5-phenyl-3-isoxazolecarboxylic acid methyl esters potentially active against drug resistant Mycobacterium tuberculosis
Sahoo, Santosh Kumar,Rani, Bandela,Gaikwad, Nikhil Baliram,Ahmad, Mohammad Naiyaz,Kaul, Grace,Shukla, Manjulika,Nanduri, Srinivas,Dasgupta, Arunava,Chopra, Sidharth,Yaddanapudi, Venkata Madhavi
, (2021/06/14)
In search of novel therapeutic agents active against emerging drug-resistant Mycobacterium tuberculosis and to counter the long treatment protocol of existing drugs, herein we present synthesis and biological evaluation of a new series of 5-phenyl-3-isoxazolecarboxylic acid methyl ester-chalcone hybrids. Among 35 synthesized compounds, 32 analogues displayed potent in-vitro activity against Mycobacterium tuberculosis H37Rv with MIC 0.12–16 μg/mL. Cell viability test against Vero cells indicated 29 compounds to be non-cytotoxic (CC50 > 20 μg/mL & SI > 10). Most potent compounds with MIC 0.12 μg/mL (7 b, 7j, 7 ab) exhibited selectivity index (SI) in excess of 320. Further studies on activity against drug-resistant Mycobacterium tuberculosis revealed 7j as the most potent compound with MIC 0.03–0.5 μg/mL. Time-kill kinetic study suggested compound 7j displaying concentration-dependent bactericidal killing activity with relatively comparable potency to that of current first-line anti-TB drugs. Taken together, 7j presents a novel hit with potential to be translated into a potent antimycobacterial.
